Organogenesis Reports Q1 2025 Financial Results

Organogenesis Holdings ( (ORGO) ) has released its Q1 earnings. Here is a breakdown of the information Organogenesis Holdings presented to its investors.

Organogenesis Holdings Inc. is a regenerative medicine company specializing in the development, manufacture, and commercialization of products for the advanced wound care and surgical & sports medicine markets.

In its first quarter of 2025 financial results, Organogenesis Holdings reported a net revenue of $86.7 million, marking a 21% decrease from the previous year. The company experienced a significant net loss of $18.8 million, a stark contrast to the $2.1 million net loss reported in the same quarter of 2024.

The decline in revenue was primarily driven by a 23% decrease in sales of Advanced Wound Care products, although this was partially offset by an 11% increase in sales of Surgical & Sports Medicine products. Operating expenses rose by 5%, and the company recorded a substantial operating loss of $26.7 million compared to the previous year’s $3.9 million.

Despite these challenges, Organogenesis remains optimistic about its future prospects. The company is progressing with its ReNu development plan and expects to submit a Biologics License Application by the end of 2025. Management is confident in navigating the evolving reimbursement landscape and executing its commercial strategy for the remainder of the year.